Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
277.33
-1.84 (-0.66%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
March 01, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals's Return On Capital Employed Insights
February 27, 2023
Via
Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
February 24, 2023
Via
Benzinga
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity
February 23, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
February 21, 2023
Via
Benzinga
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
February 21, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
February 02, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Five Best And Worst Performing Healthcare Stocks In December 2022
January 22, 2023
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst...
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
January 18, 2023
Via
Benzinga
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
January 08, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
3 Growth Stocks That Could Rocket Higher in 2023
January 06, 2023
Upcoming binary events could push these stocks to new all-time highs.
Via
The Motley Fool
Alnylam Announces Updates to its Board of Directors
January 05, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
December 21, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Meta To Rally Over 29%? Here Are 10 Other Price Target Changes For Friday
December 16, 2022
Via
Benzinga
Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
December 15, 2022
From
Alnylam Pharmaceuticals
Via
Business Wire
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
December 08, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Virtual R&D Day
December 08, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
December 06, 2022
Via
Benzinga
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022
December 01, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
November 09, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Looking Into Alnylam Pharmaceuticals's Return On Capital Employed
November 02, 2022
Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q3 sales of $264.31 million. Earnings fell to a loss of $405.92 million, resulting in a 46.33% decrease from last quarter.
Via
Benzinga
What 11 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
November 02, 2022
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
Via
Benzinga
Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year
October 27, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Scraps Interim Analysis For Heart Disease Trial, Rethinks Plans For Another Rare Disorder Program
October 27, 2022
Via
Benzinga
Alnylam Pharmaceuticals: Q3 Earnings Insights
October 27, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q3 earnings results on Thursday, October 27, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
October 27, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
Where Alnylam Pharmaceuticals Stands With Analysts
October 13, 2022
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
Via
Benzinga
Roblox To $51? Plus Deutsche Bank Slashes PT On Deere & Company
October 13, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.